MicroPort CardioFlow Medtech Corporation (MP CardioFlow) filed its Monthly Return for the period ended 31 October 2026, confirming that no changes occurred in either authorised or issued share capital during the month.

\n\nKey share capital data • Authorised share capital remained at 2.00 billion ordinary shares with a par value of USD 0.000025 each, equating to USD 50,000. • Issued share capital stood unchanged at 1.27 billion shares. • The company held no treasury shares, and no new shares were issued or cancelled.

\n\nPublic float compliance MP CardioFlow confirmed compliance with the Main Board’s minimum public-float requirement of 25% of issued shares as at 31 October 2026.

\n\nShare-based incentives • Share Option Scheme: outstanding options decreased by 12,000 to 10.32 million after cancellations; no options were exercised or granted. • Share Scheme: outstanding awards fell by 168,000 to 4.45 million following cancellations; no new grants or exercises took place. • Aggregate shares that could be issued under existing options totalled 10.20 million, with a further 40.73 million shares available for grant under the Share Scheme. • No proceeds were raised from option exercises during the month.

\n\nOther corporate actions The company reported no activity in warrants, convertible securities, share repurchases, redemptions, or Hong Kong Depositary Receipts.

\n\nAdministrative confirmation The return was signed by Joint Company Secretary Li Xiangmei on 5 November 2026, affirming compliance with applicable listing rules and regulatory requirements.